TheImpactofaNovelMethodologicalProcessforNeedlingScars,Fascia,andMusclesintheManagementofMyofascialDysfunctionandChronicPaininaPopulationLivingWithSocialandHealthInequities:QuantitativeFindingsFromaLongitudinalObservationalPilotStudy

Chronic pain is a major burden for people living with social and health inequities, who often face barriers to accessing appropriate care and may resort to unregulated drug use to self-manage their suffering. Myofascial dysfunction (MFD), involving fascial tension, muscle trigger points, and scar tissue restrictions, is frequently overlooked as a contributor to chronic pain. The Downtown East Side (DTES) of Vancouver, British Columbia, is home to a particularly vulnerable population with high rates of trauma, homelessness, substance use disorders, and limited access to healthcare. Nonpharmacological interventions are urgently needed to reduce dependence on opioids and unregulated drugs. myoActivation® is a novel systematic assessment and needling process designed to address MFD by targeting scars, fascia, and muscles using fine-gauge cutting-tip needles.

While this approach has shown promise in pediatric populations, its effectiveness had not been studied in adults with complex social and health challenges.

The researchers conducted a prospective, longitudinal, observational pilot study at the Vancouver Community Pain Service (VCPS) in the DTES. They enrolled 35 adults with chronic pain (lasting more than 3 months) who were scheduled for myoActivation treatment as part of routine clinical care. Participants were assessed at baseline (Week 1) and followed up at 4, 12, and 24 weeks. The primary outcome was the PEG score (Pain, Enjoyment of life, and General Activity), a validated 3-item measure where lower scores indicate better outcomes.

A 30% reduction in PEG was considered clinically meaningful. Secondary outcomes included the Pain Catastrophizing Scale (PCS), the Pain Self-Efficacy Questionnaire (PSEQ), and self-reported changes in substance and analgesic medication use. The myoActivation process involved a detailed trauma history (Timeline of Lifetime Trauma), posture assessment, movement tests (BASE tests), and palpation to identify areas of MFD, followed by needling of scars, fascia, and muscle trigger points. Treatment was individualized, with a median of 4 sessions per participant.

The study used linear mixed-effects models to analyze changes over time while accounting for missing data.

At baseline, participants had a median PEG score of 7.7 out of 10, indicating severe pain and interference with life. PEG scores improved significantly at every follow-up point: the mean difference from baseline was −1.8 at Week 4 (95% CI −2.6 to −0.9, p<0.001), −2.1 at Week 12 (95% CI −3.1 to −1.1, p<0.001), and −2.5 at Week 24 (95% CI −3.5 to −1.5, p<0.001). This represents a 32% improvement over the study period, exceeding the threshold for clinical significance. Pain catastrophizing (PCS) also improved, with a mean reduction of −5.6 points at Week 24 (95% CI −10.2 to −1.1, p=0.016), a 16% improvement.

Pain self-efficacy (PSEQ) improved by a mean of 3.5 points at Week 24 (95% CI 0.8 to 6.2, p=0.013), a 36% improvement. At Week 24, 9 out of 27 participants (33%) reported less unregulated drug use, and 8 out of 27 (30%) reported less analgesic medication use. Among participants treated for scars (26 out of 35, or 74%), 92% experienced somatic reactions and 54% had emotional responses including recall of traumatic memories. No serious adverse events were reported.

Follow-up rates were 77% at Week 4, 54% at Week 12, and 57% at Week 24, with some additional data obtained from electronic medical records.

This pilot study provides preliminary evidence that myoActivation, a structured dry needling approach targeting scars, fascia, and muscles, can produce clinically meaningful and sustained improvements in pain, function, and quality of life for people with chronic pain who face significant social and health inequities. The 32% reduction in PEG scores at 24 weeks is particularly notable given the complexity of this population, where 69% had substance use disorders, 49% had PTSD, and 51% were homeless or in precarious housing. The reductions in self-reported unregulated drug use and analgesic medication use, while based on small numbers, suggest potential broader public health benefits in the context of an ongoing toxic drug crisis. The emotional and somatic responses to scar needling highlight the importance of trauma-informed care and the interconnectedness of physical and psychological trauma stored in fascial tissues.

However, the lack of a control group, small sample size, and significant loss to follow-up limit causal inference. The findings support further research, ideally with randomized controlled designs and larger samples, to confirm these promising results and to explore whether myoActivation could be scaled as a point-of-care intervention in primary care settings for underserved populations.